glp-1 drugs for obesity Agonists: Using Semaglutide, Tirzepatide, and Orforglipron Weight Loss and Costly GLP-1 Drugs are Rarely

Telehealth and patient satisfaction: a systematic review and narrative analysis

Nunn E, et al

Amy Myers July 9, 2026 4:14 View More Your Home Could Be Affecting Your Health More Than You Realize The Hidden Impact of Air, Water, and Everyday Toxins with Helen Christoni July 6, 2026 4:04 View More Success Is Built One Step at a Time The Untold Story Behind Modern Thyroid Clinic with Melissa Afflerbach June 25, 2026 4:17 View More More Treatments Do Not Mean Better Results - The New Rules for Natural Looking Facial Rejuvenation with Dr

According to the World Obesity Atlas, over 4 billion people, or 51% of the global population, by 2035 will suffer from obesity

GLP-1 receptor agonists have great therapeutic potential for treating diabetes and obesity

These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids